Lonza invests in Singapore to support growth in mammalian biologics

By Jane Byrne contact

- Last updated on GMT

© GettyImages/SolStock
© GettyImages/SolStock

Related tags: mammalian manufacturing services, Lonza

Lonza is investing to expand mammalian development services at its Singapore facility; the move will bring additional capacity for cell culture, purification, and analytical services for mammalian biologics.

The addition of new technology, alongside the increase in capacity and headcount of the development services team in Singapore, will provide a comprehensive offering for small- and large-scale GMP mammalian manufacturing services and cell therapy capabilities, said the contract development and manufacturing organization (CDMO).

Current laboratory capabilities are being expanded, with a new 1,800m2​ laboratory at Singapore Science Park; the investment will also increase the headcount across the Tuas and Singapore Science Park laboratories to 125 employees.

Companies in the Asia region are looking to partners to help address specific needs and guide them towards an IND or BLA filing from early development stages, noted Lonza.

There is a huge focus on complex molecule development in the region, and such R&D work needs the latest technology for mammalian process and analytical development, which this investment has realized, it said.

Its Singapore team now has the capability to perform extensive characterization of biopharmaceuticals using mass spectrometry. Lonza said the expansion will also ensure it can  address anticipated market growth in complex protein formats.

Drug product manufacturing in China

The spend in Singapore follows the Swiss group’s announcement in August that it is to install a new drug product fill and finish manufacturing line at its Guangzhou site in China to support the filling of liquid and lyophilized products.

That installation is expected to be completed in 2022, and the move sees drug product (DP) manufacturing capacity being established for clinical trial and commercial supply in China.

Jeff Li, vice president of commercial development, Lonza, told BioPharma-Reporter, that month:

“The installation of the DP manufacturing line marks a significant milestone towards our long-term goal of increasing drug product capacity, both locally and globally. Most domestic projects need drug product manufacturing, as this is driven by local regulations. Regarding local DP demand, we see booming market needs, which are driven by commercial drugs launching in China in the future.” 

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Related suppliers

Follow us

Products

View more

Webinars